elgan pharma scam or legit? Reviews and complaints

An Investigation into Elgan Pharma

Elgan Pharma presents itself as a late-stage biotech company developing pioneering neonatal therapies. On the surface, addressing high-risk preterm infant care through non-invasive solutions seems a noble endeavor. However, some aspects of Elgan Pharma’s operations have raised red flags, leading to accusations this may be more of a scam than a legitimate medical enterprise.

Let’s take a deeper look into Elgan Pharma’s claims, products, history and other elements to understand these criticisms and determine the likelihood of illegitimate activity. While innovation in prematurity deserves support, consumers must be wary of false promises that ultimately fail or harm patients.

ELGN-GI and ELGN-EYE Therapies

Elgan Pharma’s website highlights two main therapeutic areas – ELGN-GI and ELGN-EYE. Both target common complications in preterm infants like gastrointestinal immaturity and retinopathy of prematurity (ROP).

However, digging deeper reveals:

• No published clinical trial data or peer-reviewed research on the therapies can be found. Most legitimate pharmaceutical research is published.

• Specifics on treatment protocols, drug constituents, safety/efficacy data are not disclosed, raising doubts about real product existence.

• No mention of regulatory approvals needed to commercially develop/administer medical therapies to preterm infants.

This lack of transparency and scientific substantiation for the flagship products/indications represent major red flags suggesting all may not be as portrayed.

Leadership and Operations

Elgan Pharma lists no leadership team bios or credentials. Searching finds no relevant experience in drug development, neonatology or startup biotechs for who/where the company claims to operate from.

Additionally:

• The sparse “Contact Us” page provides little verifiable contact info beyond a generic email.

• Public records searches show no incorporation or location data matching what’s shared.

• Domain registration details are obscured through services like Domains By Proxy.

These anomalies imply the operation is more of an online facade with no legitimacy beyond a promotional website. Real companies publicly establish credibility.

Social Presence

Elgan Pharma has Facebook and LinkedIn pages but both are suspiciously devoid of followers or engagement. Posts only started a year ago indicating the profiles were created solely to establish an online presence, not for real networking.

Interestingly, Google searches now return results linking Elgan Pharma to being a suspected scam. Numerous consumer complaint forums caution others. While commentary remains anonymous, consensus points toward fabrication rather than truth in marketing.

Legitimate biotechs gain attention through measurable progress, not dubious promotional tactics raising so many caution flags.

Conclusion

Viewing all the peculiarities collectively paints a concerning picture that Elgan Pharma is likely less of a serious drug developer and more of a deception perpetrating imaginary breakthroughs to mislead would-be investors or partners.

No public record backs any of the ambitious claims, product plans or locations stated. Consequently, no credible evidence suggests patients would realistically benefit as portrayed either.

In the sensitive neonatal healthcare sphere, such clouds of misrepresentation are unacceptable. Unless substantial proof emerges independently verifying Elgan Pharma’s work, affiliations and leadership, all indicators point to this “company” representing nothing more than an elaborate scam preying on hope. Parents, professionals and supporters of prematurity research deserve full transparency and honesty.

While innovation remains crucial, vigilance remains equally vital to avoid hollow promises that waste resources or raise unrealistic expectations. Going forward, a heightened degree of necessary substantiation and due diligence appears warranted regarding Elgan Pharma’s activities online and off until open skepticism can be reasonably assuaged. Predatory deception has no place in the medical domain.